All Clarivate Analytics websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
SHANGHAI – High-flying CAR T developer, Kite Pharma Inc., of Santa Monica, Calif., is making a push into China and Japan. A pair of deals – Shanghai Fosun Pharmaceutical (Group) Co. Ltd. and Daiichi-Sankyo Co. Inc. – features lead asset, KTE-C19, an anti-CD19 chimeric antigen receptor (CAR) T-cell therapy for which the company is on track to submit a BLA to the FDA later this year.